No Data
No Data
Piper Sandler Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $140
Arcturus Therapeutics (ARCT) Initiated With a Buy at Piper Sandler
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both MRNA Therapeutic Programs On Track For First Half Of 2025
Express News | Arcturus Therapeutics Holdings Inc -Phase 2 Interim Data for Both Mrna Therapeutic Programs on Track for First Half of 2025
Express News | Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
No Data